Evidence map›Paper›PMID 40180789›Full record

ReviewJournal of natural medicines2025

Exploring new natural products by utilizing untapped secondary metabolic pathways in actinomycetes.

Shotaro Hoshino

Erratum issuedAbstract readReview
In one paragraph

Review in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Shotaro HoshinoDepartment of Life Science, Faculty of Science, Gakushuin University, 1-5-1 Mejiro, Toshima-ku, Tokyo, 171-8588, Japan. shotaro.hoshino@gakushuin.ac.jp.ORCID http://orcid.org/0000-0002-7502-5072

Funding

Japan Society for the Promotion of Science JP15H01836Japan Society for the Promotion of Science JP16H06443Japan Society for the Promotion of Science JP16J01117Japan Society for the Promotion of Science JP16K13084Japan Society for the Promotion of Science JP18H02120Japan Society for the Promotion of Science JP22K20566Japan Society for the Promotion of Science JP23H04543
6 · The paper itself

Abstract

Actinomycetes have produced a variety of bioactive secondary metabolites; however, discovering new actinobacterial natural products using conventional approaches has become increasingly challenging. Meanwhile, genomic studies of actinomycetes have revealed that numerous secondary metabolite biosynthetic gene clusters (SM-BGCs) remain untapped. Thus, utilizing these secondary metabolic pathways is expected to facilitate the discovery of new actinomycetes-derived natural products. In this review, I primarily describe our research on the utilization of these untapped actinobacterial SM-BGCs and the discovery of new secondary metabolites. First, I introduce our studies on the activation of silent SM-BGCs through the co-cultivation of various actinomycetes with mycolic acid-containing bacteria (MACB), which led to the identification of 20 actinobacterial secondary metabolites, including 16 new compounds. In the latter part, I describe our recent findings on arsenic-related secondary metabolism, which has been overlooked in model actinomycetes, including the identification of a novel organoarsenic natural product, and the elucidation of its unique biosynthetic strategy, which is independent of S-adenosylmethionine (SAM)-dependent enzymes.

Indexed as

ActinobacteriaBiological ProductsMetabolic Networks and PathwaysSecondary MetabolismBiosynthetic PathwaysMultigene FamilyBiological ProductsActinomycetesBiosynthesisCombined-cultureMycolic acid-containing bacteria (MACB)Organoarsenic natural productSecondary metabolites

Identifiers

PMID40180789
PMCPMC12159101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.